Download Our DHN Survey Result 2024
Realize your Healthcare’s Digital Transformation journey with ScaleHealthTech Learn More

Glenmark Pharma Launches Anti‐Diabetic Biosimilar in India

Written by : Nikita Saha

January 4, 2024

Category Img

The launch follows the approval by the central drug authority, Drug Controller General of India (DCGI), for commercialing in the Indian Market. The biosimilar is introduced under the brand name 'Lirafit'.

Leading pharma player, Glenmark Pharmaceuticals Ltd has launched a biosimilar of the popular anti‐diabetic drug, Liraglutide, for the first time in India.

Liraglutide, classified as a glucagon-like peptide 1 receptor agonist (GLP-1 RA) drug, is recognised for its ability to enhance glucose-dependent insulin secretion and reduce inappropriate glucagon secretion.

The launch follows the approval by the central drug authority, Drug Controller General of India (DCGI), for commercialing in the Indian Market. The biosimilar is introduced under the brand name 'Lirafit'.

Further, it is set to be priced at INR 100 for a standard daily dose of 1.2mg. This pricing strategy reflects a noteworthy 70% reduction in therapy costs and is available exclusively with a prescription.

Expressing his thoughts, Alok Malik, president and business head ‐ India Formulations, Glenmark Pharmaceuticals, said, "Glenmark is proud to introduce Lirafit, a novel and affordable biosimilar of the drug liraglutide, for the first time in India. Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity.”

Globally approved for the treatment of Type 2 Diabetes mellitus in adult patients, Liraglutide has secured regulatory clearances in both the United States and the European Union.

Additionally, clinical trials have demonstrated that Liraglutide not only effectively treats Type 2 Diabetes mellitus but also yields positive impacts on cardiac and renal safety outcomes, reinforcing its efficacy as a preferred treatment for patients.

Founded in 1977, Glenmark Pharmaceuticals is a generic drug and active pharmaceutical ingredient manufacturer. The company initially sold its products in India, Russia, and Africa. Currently, it has a presence in over 80 countries.

On September 23, Indian CPG company Nirma acquired Glenmark’s API unit Glenmark Life Sciences with a deal valued at INR 5,651.5 Cr, or INR 615 per share.

This acquisition marks Nirma's entry into the API sector, expanding its pharmaceutical portfolio, which includes injectables, parenterals, and ophthalmic products, making it the company's biggest bet in the pharmaceutical sector.

In terms of ownership, Glenmark Pharma's stake in the leading API platform decreased from 82.84%. to 7.84%. However, Glenmark Pharma will procure APIs from GLS for a period of five financial years with effect from April 1, 2024

Shares of Glenmark were trading 0.33% higher at INR 900.85 per share at 10:55 am on January 4th, 2024.

About Chime India

The College of Healthcare Information Management Executives (CHIME) is an executive organization dedicated to serving senior digital health leaders. CHIME includes more than 5,000 members in 56 countries and two US territories and partners with over 150 healthcare IT businesses and professional services firms. CHIME enables its members and business partners to collaborate, exchange ideas, develop professionally and advocate the effective use of information management to improve the health and care throughout the communities they serve. CHIME's members are chief information officers (CIOs), chief medical information officers (CMIOs), chief nursing information officers (CNIOs), chief innovation officers (CIOs), chief digital officers (CDOs), and other senior healthcare leaders. The CHIME India Chapter became the first international chapter outside North America in 2016 and is now a community of over 70+ members in India. For more information, please visit


Digital Health News ( DHN) is India’s first dedicated digital health news platform launched by Industry recognized HealthTech Leaders. DHN Is Industry’s Leading Source Of HealthTech Business, Insights, Trends And Policy News.

DHN Provides In-Depth Data Analysis And Covers Most Impactful News As They Happen Across Entire Ecosystem Including Emerging Technology Trends And Innovations, Digital Health Startups, Hospitals, Health Insurance, Govt. Agencies & Policies, Pharmaceuticals And Biotech.

Contact us:

© Digital Health News 2024